Journal
BIOTECHNOLOGY JOURNAL
Volume 12, Issue 12, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.201700196
Keywords
perlecan; domain V; angiogenesis; extracellular matrix; proteoglycans
Funding
- Australian Research Council [DP150104242, LP140101056]
- Australian Research Council [LP140101056] Funding Source: Australian Research Council
Ask authors/readers for more resources
The C-terminal domain V of the extracellular matrix proteoglycan perlecan plays unique and often divergent roles in a number of biological processes, including angiogenesis, vascular cell interactions, wound healing, and autophagy. Recombinant forms of domain V have been proposed as therapeutic agents for the treatment of cancer, stroke, and the development of cardiovascular devices and bioartificial tissues. However, the effect of domain V appears to be related to the differences in domain V structure and function observed in different expression systems and environments and exactly how this occurs is not well understood. In this study, the sequence from amino acid 3626 to 4391 of the perlecan protein core, which includes domain V, is expressed in HEK-293 cells and purified as a secreted product from conditioned media. This recombinant domain V (rDV) is expressed as a proteoglycan decorated with heparan sulfate and chondroitin sulfate chains and supports endothelial cell interactions to the same extent as full-length perlecan. This expression system serves as an important model of recombinant proteoglycan expression, as well as a source of biologically active rDV for therapeutic applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available